monitoring rheumatological disease
Last reviewed 01/2018
Disease-modifying anti-rheumatic drugs (DMARDs) reduce tissue destruction by suppressing the auto-immune attack on the joints.
Serum acute phase proteins (ACP) are measured monthly to assess the effectiveness of DMARDs such as:
- methotrexate
- gold
- sulphasalazine